Multivessel Versus Culprit-Only Revascularization in STEMI and Multivessel Coronary Artery Disease: Meta-Analysis of Randomized Trials
- PMID: 32646699
- DOI: 10.1016/j.jcin.2020.04.055
Multivessel Versus Culprit-Only Revascularization in STEMI and Multivessel Coronary Artery Disease: Meta-Analysis of Randomized Trials
Abstract
Objectives: The goal of this systematic review and meta-analysis was to provide a comprehensive evaluation of contemporary randomized trials addressing the efficacy and safety of multivessel versus culprit vessel-only percutaneous coronary intervention (PCI) among patients presenting with ST-segment elevation myocardial infarction and multivessel coronary artery disease.
Background: Multivessel coronary artery disease is present in about one-half of patients with ST-segment elevation myocardial infarction. Randomized controlled trials comparing multivessel and culprit vessel-only PCI produced conflicting results regarding the benefits of a multivessel PCI strategy.
Methods: A comprehensive search for published randomized controlled trials comparing multivessel PCI with culprit vessel-only PCI was conducted on ClinicalTrials.gov, PubMed, Web of Science, EBSCO Services, the Cochrane Central Register of Controlled Trials, Google Scholar, and scientific conference sessions from inception to September 15, 2019. A meta-analysis was performed using a random-effects model to calculate the risk ratio (RR) and 95% confidence interval (CI). Primary efficacy outcomes were all-cause mortality and reinfarction.
Results: Ten randomized controlled trials were included, representing 7,030 patients: 3,426 underwent multivessel PCI and 3,604 received culprit vessel-only PCI. Compared with culprit vessel-only PCI, multivessel PCI was associated with no significant difference in all-cause mortality (RR: 0.85; 95% CI: 0.68 to 1.05) and lower risk for reinfarction (RR: 0.69; 95% CI: 0.50 to 0.95), cardiovascular mortality (RR: 0.71; 95% CI: 0.50 to 1.00), and repeat revascularization (RR: 0.34; 95% CI: 0.25 to 0.44). Major bleeding (RR: 0.92; 95% CI: 0.50 to 1.67), stroke (RR: 1.15; 95% CI: 0.65 to 2.01), and contrast-induced nephropathy (RR: 1.25; 95% CI: 0.80 to 1.95) were not significantly different between the 2 groups.
Conclusions: Multivessel PCI was associated with a lower risk for reinfarction, without any difference in all-cause mortality, compared with culprit vessel-only PCI in patients with ST-segment elevation myocardial infarction.
Keywords: ST-segment elevation myocardial infarction; cardiovascular mortality; contrast-induced nephropathy; culprit vessel–only revascularization; major adverse cardiac events; multivessel coronary artery disease; multivessel revascularization; reinfarction; repeat revascularization.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Complete Revascularization in STEMI: Why, How, and When?JACC Cardiovasc Interv. 2020 Jul 13;13(13):1583-1585. doi: 10.1016/j.jcin.2020.05.022. JACC Cardiovasc Interv. 2020. PMID: 32646700 No abstract available.
-
Multivessel Versus Culprit-Only Revascularization in STEMI: Is "Treat Them All" A Right Strategy?JACC Cardiovasc Interv. 2020 Oct 12;13(19):2308. doi: 10.1016/j.jcin.2020.07.028. JACC Cardiovasc Interv. 2020. PMID: 33032716 No abstract available.
-
Impact of Complete Revascularization on Hard Outcomes in Patients With ST-Segment Elevation Myocardial Infarction.JACC Cardiovasc Interv. 2020 Oct 12;13(19):2308-2309. doi: 10.1016/j.jcin.2020.08.003. JACC Cardiovasc Interv. 2020. PMID: 33032717 No abstract available.
-
Reply: Multivessel Versus Culprit-Only Revascularization in STEMI and Multivessel Coronary Artery Disease and Impact of Complete Revascularization on Hard Outcomes in Patients With STEMI.JACC Cardiovasc Interv. 2020 Oct 12;13(19):2309-2310. doi: 10.1016/j.jcin.2020.08.032. JACC Cardiovasc Interv. 2020. PMID: 33032718 No abstract available.
Similar articles
-
Complete versus culprit-only revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: a meta-analysis of randomized trials.BMC Cardiovasc Disord. 2019 Apr 22;19(1):91. doi: 10.1186/s12872-019-1073-8. BMC Cardiovasc Disord. 2019. PMID: 31010423 Free PMC article.
-
Complete or Culprit-Only Revascularization for Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis of Randomized Trials.JACC Cardiovasc Interv. 2017 Feb 27;10(4):315-324. doi: 10.1016/j.jcin.2016.11.047. JACC Cardiovasc Interv. 2017. PMID: 28231899 Review.
-
Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta-Analysis and Meta-Regression of Randomized Trials.JACC Cardiovasc Interv. 2018 May 14;11(9):833-843. doi: 10.1016/j.jcin.2018.02.028. JACC Cardiovasc Interv. 2018. PMID: 29747913
-
Culprit Vessel-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment-Elevation Myocardial Infarction: A Collaborative Meta-Analysis.Circ Cardiovasc Interv. 2017 Nov;10(11):e005582. doi: 10.1161/CIRCINTERVENTIONS.117.005582. Circ Cardiovasc Interv. 2017. PMID: 29146672 Review.
-
Complete Revascularization by Percutaneous Coronary Intervention for Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: An Updated Meta-Analysis of Randomized Trials.J Am Heart Assoc. 2020 Jun 16;9(12):e015263. doi: 10.1161/JAHA.119.015263. Epub 2020 Jun 1. J Am Heart Assoc. 2020. PMID: 32476540 Free PMC article.
Cited by
-
Complete Revascularization of Stable STEMI Patients Offers a Significant Benefit if Done During the Index PCI, but Not if It's Done as a Staged Procedure.Int J Gen Med. 2021 Jun 3;14:2239-2248. doi: 10.2147/IJGM.S308385. eCollection 2021. Int J Gen Med. 2021. PMID: 34113153 Free PMC article.
-
The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis.Ther Adv Chronic Dis. 2022 Mar 10;13:20406223221078088. doi: 10.1177/20406223221078088. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35295615 Free PMC article.
-
Does multivessel revascularization fit all patients with STEMI and multivessel coronary artery disease? A systematic review and meta-analysis.Int J Cardiol Heart Vasc. 2021 Jun 11;35:100813. doi: 10.1016/j.ijcha.2021.100813. eCollection 2021 Aug. Int J Cardiol Heart Vasc. 2021. PMID: 34169144 Free PMC article. Review.
-
Multivessel vs. culprit vessel-only percutaneous coronary intervention in ST-segment elevation myocardial infarction with and without cardiogenic shock.Front Cardiovasc Med. 2022 Nov 24;9:992456. doi: 10.3389/fcvm.2022.992456. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36505378 Free PMC article.
-
Acute Myocardial Infarction and Cardiogenic Shock Interventional Approach to Management in the Cardiac Catheterization Laboratories.Curr Cardiol Rev. 2022;18(2):e251121198293. doi: 10.2174/1573403X17666211125090929. Curr Cardiol Rev. 2022. PMID: 34823461 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous